Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949086 | 0.89 | CA2 (0.43) | CA2CA1 | |
| SCHEMBL4949681 | 0.89 | CA2 (0.43) | CA2CA1 | |
| SCHEMBL4953881 | 0.89 | CA2 (0.43) | CA2CA1 | |
| SCHEMBL1759312 | 0.87 | CA2 (0.42) | TSHRMAPK1CA2CA1 | |
| Ammonia Solution, Strong SCHEMBL28986366 | 0.85 | CA2 (0.41) | CA2CA1 | |
| SCHEMBL1032931 | 0.82 | CA2 (0.47) | CA2CA1 | |
| SCHEMBL1759099 | 0.81 | CA2 (0.39) | CA2CA1 | |
| SCHEMBL18856639 | 0.79 | CA2 (0.40) | CA2CA1 | |
| SCHEMBL1759039 | 0.79 | CA2 (0.38) | CA2CA1 | |
| SCHEMBL13341075 | 0.78 | CA2 (0.40) | TSHRCA2CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9017645-B2 | Homoglutamic acid derivatives | PIRAMAL IMAGING SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20130071327-A1 | HOMOGLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-03-21 | — | — | US | disclosed |
| EP-2499113-A1 | HOMOGLUTAMIC ACID DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011057986-A1 | HOMOGLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2322500-A1 | Fluoro-labeled homo-glutamate derivatives and precursors thereof | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322514-A1 | Homoglutamic acid and glutamic acid derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071327-A1 | HOMOGLUTAMIC ACID DERIVATIVES | FGB, GGCT, RIMKLA | MEN1 137/4885KMT2A 1909/4885TSHR 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.